predictive oncology (nasdaq: poai) is focused on the use of data and artificial intelligence (ai) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcome. the company has several tools that support its mission of bringing precision medicine to the diagnosis of cancer. through its subsidiaries, predictive oncology’s portfolio of assets includes the following: - a database of clinically validated historical and outcome data from patient tumors - an in-house clinical laboratory improvement amendments (clia)-certified lab - a “smart” patient-derived tumor profiling platform - an in-house bioinformatics artificial intelligence (ai) platform - a new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options - an fda-approved fluid collection and disposal system using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries
Company profile
Ticker
POAI
Exchange
Website
CEO
Carl Schwartz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
Former names
BioDrain Medical, Inc., Precision Therapeutics Inc., Skyline Medical Inc.
SEC CIK
Corporate docs
Subsidiaries
Helomics Corporation • Skyline Medical, Inc. ...
IRS number
331007393
POAI stock data
Latest filings (excl ownership)
8-K/A
Submission of Matters to a Vote of Security Holders
22 Mar 24
8-K
Departure of Directors or Certain Officers
8 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
4 Jan 24
DEF 14A
Definitive proxy
7 Dec 23
PRE 14A
Preliminary proxy
5 Dec 23
8-K
Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Departure of Directors or Certain Officers
17 Aug 23
8-K
Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
Transcripts
POAI
Earnings call transcript
2023 Q3
14 Nov 23
POAI
Earnings call transcript
2023 Q2
10 Aug 23
POAI
Earnings call transcript
2023 Q1
15 May 23
POAI
Earnings call transcript
2022 Q4
22 Mar 23
POAI
Earnings call transcript
2022 Q3
11 Nov 22
POAI
Earnings call transcript
2022 Q2
12 Aug 22
POAI
Earnings call transcript
2019 Q2
19 Aug 19
POAI
Earnings call transcript
2019 Q1
15 May 19
POAI
Earnings call transcript
2018 Q4
1 Apr 19
POAI
Earnings call transcript
2018 Q3
16 Nov 18
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.92 mm | 11.92 mm | 11.92 mm | 11.92 mm | 11.92 mm | 11.92 mm |
Cash burn (monthly) | 949.57 k | 1.12 mm | 1.05 mm | 1.55 mm | 1.03 mm | 1.11 mm |
Cash used (since last report) | 5.66 mm | 6.70 mm | 6.27 mm | 9.22 mm | 6.17 mm | 6.63 mm |
Cash remaining | 6.25 mm | 5.21 mm | 5.64 mm | 2.70 mm | 5.74 mm | 5.28 mm |
Runway (months of cash) | 6.6 | 4.6 | 5.4 | 1.7 | 5.5 | 4.8 |
Institutional ownership, Q3 2023
9.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 4 |
Closed positions | 0 |
Increased positions | 3 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 1.13 bn |
Total shares | 368.70 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 140.60 k | $449.93 mm |
Raymond James & Associates | 118.23 k | $378.33 mm |
Geode Capital Management | 37.47 k | $119.94 mm |
RB Capital Management | 20.84 k | $66.67 mm |
Renaissance Technologies | 16.88 k | $54.00 k |
STT State Street | 16.84 k | $53.88 mm |
Susquehanna International | 12.27 k | $39.25 mm |
UBS UBS Group AG - Registered Shares | 2.47 k | $7.90 mm |
Advisor | 1.53 k | $4.88 mm |
Tower Research Capital | 694.00 | $2.22 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Oct 23 | Charles Lee Nuzum Sr | Common Stock | Grant | Acquire A | No | No | 0 | 2,605 | 0.00 | 26,638 |
2 Oct 23 | Handley Daniel E | Common Stock | Grant | Acquire A | No | No | 0 | 1,875 | 0.00 | 14,665 |
2 Oct 23 | Clair Gregory SR ST. | Common Stock | Grant | Acquire A | No | No | 0 | 1,875 | 0.00 | 17,934 |
2 Oct 23 | Nancy Chung-welch | Common Stock | Grant | Acquire A | No | No | 0 | 1,875 | 0.00 | 16,960 |
2 Oct 23 | Matthew Hawryluk | Common Stock | Grant | Acquire A | No | No | 0 | 1,875 | 0.00 | 7,135 |